Scientific Advisory Board

Brian Kay, Ph.D. (Chair)

Dr. Kay is a professor of biology and a world expert in the field of molecular recognition, the science of how proteins selectively interact with each other inside cells. His research group of 13 individuals utilizes phage displayed libraries of combinatorial peptides, antibody fragments, and engineered proteins to probe the surfaces of proteins and identify contact sites for binding. This approach is being currently applied to develop biosensors for protein kinases, create tools to study protein expression in cells and organisms, generate affinity reagents to bacterial and human membrane proteins, and develop diagnostics for monitoring laser-induced eye damage. He has authored 110 scientific reports and reviews, co-edited three books, and been issued 15 patents. For the past five years, he has served as head as the Department of Biological Sciences at the University of Illinois at Chicago.

Lee E. Babiss, Ph.D.

Dr. Babiss has been an Executive Vice President of Global Laboratory Services at Pharmaceutical Product Development Inc. since February 2010. Dr. Babiss provides strategic direction and additional scientific leadership to Pharmaceutical Product Development’s bioanalytical, cGMP and global central laboratories, vaccines and biologics operations and to BioDuro, which was acquired by PPD last year. He served as Head of Global Pharma Research at Roche Holding.

Ulf Landegren, M.D.

Dr. Landegren received his MD and Ph.D. in cellular immunology at Uppsala University, Sweden, followed by a postdoc at the California Institute of Technology in the USA. He is currently professor of molecular medicine at Uppsala University, where he is developing and applying advanced molecular tools for analyzing nucleic acids and proteins in research and medical diagnostics. Over the years his lab has established a series of important molecular procedures, and the lab is increasingly engaged in bringing the methods to medical application by interacting with clinicians and with the biotech and pharma industries.

David Weitz, Ph.D.

Dr. Weitz is the Mallingkrodt Professor of Physics and Applied Physics at Harvard University, where he has appointment in both the Physics Department and the School of Engineering and Applied Sciences. He received his Ph.D. in physics from Harvard, and then worked at Exxon Research and Engineering for nearly 18 years. He then was a professor of Physics at the University of Pennsylvania before joining to Harvard, where he leads the experimental soft condensed matter physics research group. His research efforts include soft matter physics, biophysics and biotechnology. He is Director of Harvard’s NSF-funded Materials Research Science and Engineering Center, and co-Director of the BASF Advanced Research Initiative and the Kavli Institute of Bionano Science and Technology. He is a member of the National Academies of Science and the American Academy of Arts and Science.

Michael Snyder, Ph.D.

Dr. Snyder is the Stanford Ascherman Professor and Chair of Genetics and the Director of the Center of Genomics and Personalized Medicine. He is a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has launched many technologies in genomics and proteomics. These include the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated, and a high diversity of transcription factor binding occurs both between and within species.